P/E Ratio
Higher than 63% of Healthcare sector peers
Updated 22h ago
Sector Performance
63th percentileVEEV
27.1x
Sector Median
24.6x
Sector Avg
28.9x
Deep Analysis
The P/E ratio (price-to-earnings) tells you how much investors are willing to pay for each dollar of a company’s earnings.
At 27.1x, VEEV trades above its Healthcare sector median of 24.6x, placing it in the 63rd percentile among peers — meaning it is more expensive than about 63% of comparable companies. Year-over-year change is not available, but the ratio declined 3.5% quarter-over-quarter (from 28.1x to 27.1x), indicating the multiple is compressing. Although the current level is elevated relative to the sector, the downward trend reduces valuation risk by making the stock cheaper than it was last quarter. This pattern supports the overall BULLISH verdict because a falling P/E can signal improving earnings growth or a cooling of previous exuberance, making entry more attractive.
Frequently Asked Questions
What does the P/E Ratio tell investors about VEEV?
Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.
How is the P/E Ratio calculated?
P/E Ratio is calculated as: Price / EPS.
How does VEEV's P/E Ratio compare to its sector?
VEEV's P/E Ratio of 27.1x compares to a Healthcare sector median of 24.6x, placing it in the 63th percentile.
Who are VEEV's closest peers by P/E Ratio?
The closest Healthcare peers by P/E Ratio include: TMO (24.6x), AMGN (24.7x), BSX (25.8x), A (23.0x), AZN (27.0x).
The Formula
Price / EPS
Why It Matters
Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.
Master VEEV's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full VEEV research report →VEEV
27.1x
Sector Median
24.6x
Sector Avg
28.9x
How VEEV's P/E Ratio compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.